Neuropsychiatric Complications of Stimulant Abuse, Volume 120 [Kõva köide]

Volume editor (Tartu University Hospital, Estonia), Volume editor (North-Estonian Regional Hospital, Estonia), Volume editor (University College London, UK)
  • Formaat: Hardback, 402 pages, kõrgus x laius x paksus: 229x152x23 mm, kaal: 770 g, black & white illustrations
  • Sari: International Review of Neurobiology 120
  • Ilmumisaeg: 27-May-2015
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0128029781
  • ISBN-13: 9780128029787
  • Kõva köide
  • Hind: 168,00 EUR
  • Lisa soovinimekirja
  • Lisa ostukorvi
  • Kogus:
  • Tasuta tarne
  • Tellimisaeg 2-4 nädalat
  • Raamatut on võimalik tellida. Raamatu kohalejõudmiseks kirjastusest kulub orienteeruvalt 2-4 nädalat.
  • Raamatukogudele
    • EBL
  • Formaat: Hardback, 402 pages, kõrgus x laius x paksus: 229x152x23 mm, kaal: 770 g, black & white illustrations
  • Sari: International Review of Neurobiology 120
  • Ilmumisaeg: 27-May-2015
  • Kirjastus: Academic Press Inc
  • ISBN-10: 0128029781
  • ISBN-13: 9780128029787
This well-established international series examines major areas of basic and clinical research within neuroscience, as well as emerging and promising subfields. This volume concentrates on the neuropsychiatric complications of stimulant abuse.
  • Brings together cutting-edge research on the neuropsychiatric complications of stimulant abuse

Muu info

The book 'The neuropsychiatric complications of stimulant abuse' gives a broad overview on effects of psychostimulants that may lead to disastrous neurological and psychiatric consequences causing a permanent harm when misused. However, their potential to enhance cognition could perhaps still lead to an expanded beneficial role.
Contributors xi
1 The Story of "Speed" from "Cloud Nine" to Brain Gain
1(8)
Andrew Lees
Katrin Sikk
Pille Taba
References
6(3)
2 Amphetamine-Type Stimulants: The Early History of Their Medical and Non-Medical Uses
9(18)
Nicolas Rasmussen
1 Introduction
10(1)
2 Early History of the Amphetamines
10(2)
3 Wakefulness, Attention, and Cognitive Performance
12(1)
4 Mood Elevation
13(1)
5 Appetite Suppression
14(2)
6 Military Use: "Combat Fatigue" and the Second World War
16(3)
7 Nonmedical Use, Abuse, and Dependence
19(3)
8 Conclusion
22(5)
Acknowledgment
23(1)
References
23(4)
3 Miracle or Menace? The Arrival of Cocaine 1860--1900
27(14)
Mike Jay
References
38(3)
4 Psychostimulants: Basic and Clinical Pharmacology
41(44)
Andrew C. McCreary
Christian P. Muller
Malgorzata Filip
1 Introduction
42(1)
2 Human and Animal Effects of Psychostimulants
42(1)
3 Chemistry and Pharmacology of Psychostimulants
43(8)
4 Psychostimulant Use Versus Abuse
51(6)
5 Strategies for the Treatment of Psychostimulant Use Disorder: Clinical and Nonclinical Approaches, Evolving Targets
57(14)
6 Concluding Remarks
71(14)
References
72(13)
5 Epigenetic Mechanisms of Psychostimulant-Induced Addiction
85(22)
Anti Kalda
Alexander Zharkovsky
1 Introduction
86(1)
2 Epigenetic Processes
86(1)
3 Chromatin Structure
87(1)
4 Histone Modifications
88(3)
5 DNA Methylation and Demethylation
91(2)
6 Noncoding RNA
93(1)
7 Epigenetic Mechanisms In Psychostimulant-Induced Addiction
93(7)
8 Conclusions
100(7)
References
100(7)
6 Experimental Models on Effects of Psychostimulants
107(24)
Sulev Koks
1 Introduction
108(1)
2 Changes In the Brain in Response to Psychostimulants
108(2)
3 Animal Models
110(2)
4 Psychostimulant Animal Models
112(1)
5 Animal Models to Analyze Reinforcing Properties
113(3)
6 Conditioned Place Preference
116(2)
7 Drug Discrimination as a Tool to Measure Subjective Effects
118(1)
8 Animal Models for Drug Withdrawal
119(1)
9 Toxicity of Psychostimulants
119(3)
10 Conclusions
122(9)
References
122(9)
7 Neurologic Complications of Psychomotor Stimulant Abuse
131(30)
Juan Sanchez-Ramos
1 Historical Overview
132(4)
2 Neuropharmacology
136(2)
3 Stimulant Abuse, Tolerance, and Dependence
138(4)
4 Stimulants and Movement Disorders
142(5)
5 Serious Adverse Effects Leading to Emergency Room Visits and Hospitalizations
147(5)
6 Summary
152(9)
Acknowledgment
153(1)
References
153(8)
8 Neurobehavioral Sequelae of Psychostimulant Abuse
161(18)
Atbin Djamshidian
1 Introduction
161(1)
2 Psychostimulant Addiction
162(3)
3 Psychiatric Complications Seen in Psychostimulant Abusers
165(1)
4 Theories of Addiction
165(2)
5 Neurocircuitry of Addiction
167(2)
6 Neuropsychological Changes
169(3)
7 Conclusions
172(7)
References
173(6)
9 Neuropsychiatric Adverse Effects of Amphetamine and Methamphetamine
179(26)
Jaanus Harro
1 Introductory Remarks
180(2)
2 Short-Term Effects
182(1)
3 Drug Use Disorder and Predisposition
183(2)
4 Psychosis
185(1)
5 Cognition, Affect, and Suicidality
186(1)
6 Neuropsychiatric Correlates of Adverse Effects
187(7)
7 Comorbidity
194(11)
References
197(8)
10 "Addicted to Euphoria": The History, Clinical Presentation, and Management of Party Drug Misuse
205(30)
Jenny Bearn
Matthew O'Brien
1 Historical Aspects of Party Drug Use
206(5)
2 Epidemiology of Party Drug Use
211(1)
3 Recreational Use Versus Dependence
212(2)
4 Party Drugs: Subjective Effects and Hazards of use
214(14)
5 The Future of Party Drugs
228(7)
References
228(7)
11 "Natural Amphetamine" Khat: A Cultural Tradition or a Drug of Abuse?
235(22)
Nilesh B. Patel
1 Introduction
236(5)
2 The Prevalence of Khat Use
241(1)
3 Phytochemistry of Catha edulis Forsk
241(3)
4 The Pharmacokinetics of Khat
244(1)
5 The Neurochemistry of Khat
245(1)
6 Effects on Neonatal Development
246(2)
7 Effect on Cognitive and Executive Function in Humans After Khat Exposure
248(1)
8 Khat Use and Psychosis
249(1)
9 Dependence
249(1)
10 Cultural Tradition or Drug of Abuse?
250(7)
Acknowledgment
251(1)
References
251(6)
12 Methcathinone "Kitchen Chemistry" and Permanent Neurological Damage
257(16)
Katrin Sikk
Pille Taba
1 Introduction
258(1)
2 Synthesis of Methcathinone
259(1)
3 Effects of Methcathinone Intoxication
260(1)
4 Role of Manganese in Methcathinone Intoxication
260(2)
5 Prevalence of Parkinsonism in Methcathinone Abusers
262(1)
6 Clinical Symptomatology
262(1)
7 Neuroimaging and Biomarkers of Exposure
263(3)
8 Treatment
266(1)
9 Conclusions
267(6)
References
267(6)
13 "Legal Highs" -- An Emerging Epidemic of Novel Psychoactive Substances
273(28)
Jolanta B. Zawilska
1 Introduction
274(2)
2 Psychostimulants
276(12)
3 Synthetic Cannabinoids
288(5)
4 Management of Acute Intoxication with NPS
293(8)
References
293(8)
14 Psychostimulants and Artistic, Musical, and Literary Creativity
301(26)
Iain Smith
1 Introduction
302(1)
2 Creativity Research
303(2)
3 Stages of the Creative Process
305(1)
4 Drugs, Creativity, and Cultural History
306(3)
5 Drug Discovery and Synthesis
309(1)
6 Psychostimulants and Creativity
310(1)
7 Psychostimulants, Literature, and Literary Scenes
311(8)
8 Other Stimulant Drugs
319(1)
9 The Visual Arts
320(1)
10 Psychostimulants and Popular Music
321(1)
11 Conclusion
322(5)
References
323(4)
15 Opium as a Literary Stimulant: The Case of Samuel Taylor Coleridge
327(12)
Neil Vickers
1 The Case of Coleridge
332(7)
References
337(2)
Index 339(6)
Contents of Recent Volumes 345
Dr Pille Taba is an Associate Professor of Neurology of the University of Tartu, President of the Estonian Society of Neurologists and Neurosurgeons, and Head of the Neurology Commission for the Estonian Ministry of Social Affairs. She serves as a member of the Education Committee and Secretary Elect of European Section of the International Movement Disorders Society, and of the Scientific Advisory Group of Neurology of the European Medicines Agency. Dr Pille Taba was graduated from the University of Tartu, Estonia, and received her postgraduate medical training at the University of Vienna, the Karlstad University Hospital, and the Minneapolis Clinic of Neurology. Her research interests have been focused on movement disorders: Parkinson's disease and toxic parkinsonism, in collaboration with the University College London and University of Helsinki, and neuropinfections. Pille Taba has been an invited speaker at many international congresses and educational courses. Professor of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square and Emeritus Director, Reta Lila Weston Institute of Neurological Studies, University College London, Institute of Neurology Born on Merseyside Andrew Lees qualified in medicine at the Royal London Hospital Medical College in 1970. His neurological training was at University College London Hospitals and the National Hospital for Neurology and Neurosurgery, Queen Square. He also spent time at L'Hopital Salpetriere in Paris. At the age of thirty-two he was appointed to the consultant staff at the National Hospitals, The Middlesex, and Whittington Hospitals and in 1987 he was elected a Fellow of the Royal College of Physicians. He was later appointed Professor of Neurology at the National Hospital for Neurology and Neurosurgery, Queen Square and in 1998 became Director of the Reta Lila Weston Institute for Neurological Studies. He is Clinical Director of the Queen Square Brain Bank for Neurological Disorders and Director of the Sara Koe PSP Research Centre. Professor Lees is a Visiting Professor at the University of Liverpool and has close collaborations with a number of Brazilian universities. For his contributions to Brazilian neurology he was elected an overseas member of the Academia Nacional de Medicina and the Academia Brasileira de Neurologica. He has been elected as a Council member of the Academy of Medical Sciences 2012, and received a NIHR Senior Investigators Award in 2008. He has achieved international recognition for his work on Parkinson's disease and abnormal movement disorders and was elected President of the Movement Disorder Society (2004-2006). He was co-editor in chief of the Movement Disorders Journal from 1995- 2003. In 2006, he was awarded the Movement Disorders Research Award by the American Academy of Neurology. In the last four years he has delivered the Gowers Memorial Lecture at the National Hospital, The inaugural Lord Brain Memorial Lecture at Barts and the Royal London Hospitals and David Marsden Memorial Lecture at the EFNS. He was the recipient of Stanley Fahn Lectureship Award, MDS Dublin 2012, and has been awarded the German Society of Neurology's 2012 Dingebauer Prize for outstanding scientific attainment in the field of Parkinson's disease and Neurodegenerative Disorders. In December 2013 he delivered the 11th Ludvig Puusepp Memorial Lecture at the University of Tartu, Estonia. He is an original member of the Highly Cited Researchers ISI Databasewith an h-index of 100. Katrin Sikk works as a general neurologist in North Estonian Regional Hospital. She was graduated from Tartu University in 1999 and completed the residency in neurology in 2006. She received her doctoral degree in medicine from Tartu University in 2013. The study was about parkinsonian syndrome realted to intravenous use of "designer psychostimulant" methcathinone, derived from pseudoephedrine using potassium permanganaate as the oxidant. Her main interests are movement disorders and toxic parkinsonism. She is member on the board of the Estonian Movement Disorder's Society.

Tellige see raamat tutvumiseks TÜ Raamatupoodi!Raekoja plats 11, 51004 Tartu

Juhul, kui teie arvates võiks see raamat olla müügis ka Tartu Ülikooli Raamatupoes või soovite lihtsalt raamatuga enne ostu tutvuda, siis palun sisestaga allpool oma nimi ning e-mail. Võimaluse korral tellime raamatu poodi ning teavitame ka teid, kui raamat on müügile jõudnud.

* - väljad on kohustuslikud